Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Read Article
News
2024
2023
Archive
Search news articles
November 17, 2014
DATA FROM EPIRUS’ PHASE 3 STUDY OF BOW015, A BIOSIMILAR INFLIXIMAB, TO BE PRESENTED AS A LATE BREAKING POSTER AT THE AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING
November 17, 2014
RELYPSA ANNOUNCES KEY DATA PRESENTED PRESENTED AT ASN ON LONG-TERM CHRONIC TREATMENT AND EARLY ONSET OF ACTION WITH PATIROMER FOR ORAL SUSPENSION
November 11, 2014
5AM VENTURES ANNOUNCES VENTURE PARTNER AND CFO APPOINTMENTS
November 10, 2014
NOVIRA THERAPEUTICS ANNOUNCES PRESENTATION OF PHASE 1A SAFETY AND PHARMACOKINETIC DATA FOR NVR 3-778
October 22, 2014
RELYPSA SUBMITS NEW DRUG APPLICATION TO U.S. FDA SEEKING APPROVAL FOR PATIROMER FOR ORAL SUSPENSION TO TREAT HYPERKALEMIA
September 25, 2014
EPIRUS AND LIVZON MABPHARM, INC. ENTER COLLABORATION AGREEMENT FOR CHINA
September 23, 2014
EPIRUS ANNOUNCES POSITIVE 58 WEEK FOLLOW UP DATA FOR BOW015 FOR TREATMENT OF RHEUMATOID ARTHRITIS
September 17, 2014
ACHAOGEN ANNOUNCES FIRST PATIENT ENROLLMENT IN A PHASE 3 CLINICAL TRIAL OF PLAZOMICIN TO TREAT INFECTIONS CAUSED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)
September 9, 2014
FLEXION THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. COMPOSITION OF MATTER PATENT FOR LEAD CANDIDATE FX006
September 4, 2014
NOVIRA THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1A CLINICAL STUDY ON NVR-1221 AND COMMENCEMENT OF PHASE 1B CLINICAL STUDIES
« Previous Page
1
…
99
100
101
102
103
…
118
Next Page »